What Response Biomedical does

Response Biomedical Corp. is a privately held Canadian in-vitro diagnostics company founded in 1992 and headquartered in Vancouver, British Columbia. The company develops, manufactures, and commercializes rapid point-of-care diagnostic tests built around its proprietary RAMP (Rapid Analyte Measurement Platform) — a quantitative, self-calibrating immunoassay system that delivers lab-quality results in approximately 15 minutes directly from whole-blood samples without centrifugation. Its product portfolio spans five therapeutic categories: cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19 antigen), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika, CDC-validated). The core RAMP 200 instrument is a modular analyzer supporting 2, 4, or 6 simultaneous tests, with LIS connectivity, built-in QC, and a RAMP Portal for data management.

The company's go-to-market is primarily indirect, relying on a global network of channel partners led by a dedicated VP of Global Channel Strategy. End customers include acute care hospitals, emergency departments, clinical laboratories, public-health and vector-control programs, and women's health clinics. Pricing is quote-based with multi-year contracts. Response Biomedical holds ISO 13485:2016 and MDSAP certifications and has secured Health Canada approval for its COVID-19 antigen test. Recent strategic activity includes a March 2026 collaboration with Korea's Sugentech (KOSDAQ: 253840) and the June 2026 launch of the RAMP Xpress platform, which extends the franchise beyond acute care into chronic disease and wellness management.

Name

Response Biomedical

Legal name

Response Biomedical Corp.

Website

https://responsebio.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Response Biomedical develops and manufactures rapid point-of-care diagnostic tests built on its proprietary RAMP immunoassay platform, serving acute-care hospitals, clinical laboratories, and public-health programs through a global channel-partner network from its Vancouver, Canada base.

Ownership category

akta.pro rank

Product category

Point-of-Care In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hematology & Coagulation Diagnostics (HLAHAAAB)

akta.pro secondary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

• Point-of-care diagnostics
• In vitro diagnostics
• Cardiovascular testing
• Infectious disease testing
• Rapid diagnostic tests

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Test Kits and Platform Sales: Response Biomedical generates revenue through the sale of its RAMP diagnostic test kits and RAMP 200 analyzers. The company offers tests across cardiovascular, sepsis, infectious disease, women's health, and arbovirus categories. Tests are sold to healthcare facilities, clinical laboratories, and vector control programs.
2. Channel Partner Sales: Revenue generated through a network of channel partners who distribute RAMP products in their respective markets. Partners receive diagnostic tests and exceptional support levels.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Response Biomedical develops, manufactures, and markets the RAMP (Rapid Analyte Measurement Platform) line of rapid, quantitative, self-calibrating diagnostic tests and analyzers for point-of-care use. The company produces the RAMP 200 modular analyzer (configurable for 2, 4, or 6 parallel tests) plus a portfolio of immunoassay cartridges covering cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika) indications, designed to deliver lab-quality results from whole blood in approximately 15 minutes without centrifugation or maintenance contracts.

Product overview

Response Biomedical offers a platform-plus-tests architecture centered on the RAMP 200 rapid diagnostic system. The RAMP 200 is a self-calibrating, quantitative point-of-care platform that delivers lab-quality results in approximately 15 minutes from whole blood samples. This core platform runs a comprehensive portfolio of diagnostic tests organized across five therapeutic categories: Cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), Sepsis (Procalcitonin), Infectious Disease (Flu A+B, RSV, COVID-19), Women's Health (Total β-hCG), and Arbovirus testing. The company has recently expanded into chronic disease management with the launch of the RAMP Xpress platform. Accessories include barcode scanners and printers. All tests are designed for point-of-care use in acute care settings.

Differentiator

Problem solved

Functional benefit

Brands

• RAMP: The RAMP platform is a global leader in acute care diagnostic testing for triage directly from whole blood samples. It includes rapid, quantitative, self-calibrating analyzers like the RAMP 200.

Products and services

• RAMP 200 Analyzer Rapid, quantitative, self-calibrating diagnostic analyzer providing lab-quality results from whole blood in approximately 15 minutes with modular 2/4/6 test ports, built-in QC, no maintenance, and LIS connectivity; designed for acute care hospitals, clinical labs, and point-of-care settings.
• RAMP Troponin I Test Quantitative cardiovascular immunoassay cartridge for cardiac troponin I used to triage patients suspected of myocardial infarction in acute care settings.
• RAMP NT-proBNP Test Quantitative cardiovascular immunoassay cartridge for N-terminal pro-B-type natriuretic peptide used in the evaluation of heart failure and cardiac function.
• RAMP D-Dimer Test Quantitative coagulation immunoassay cartridge for D-dimer used in the diagnosis of deep vein thrombosis and pulmonary embolism.
• RAMP CK-MB Test Quantitative cardiovascular immunoassay cartridge for creatine kinase-MB isoenzyme used as an adjunct test for cardiac injury assessment.
• RAMP Myoglobin Test Quantitative cardiovascular immunoassay cartridge for myoglobin, an early marker of muscle damage including cardiac muscle injury.
• RAMP Procalcitonin Test Quantitative sepsis immunoassay cartridge for procalcitonin used for early sepsis diagnosis and monitoring in emergency and in-patient settings.
• RAMP Flu A+B Test Immunoassay cartridge for rapid detection of influenza A and B viruses, developed in collaboration with 3M.
• RAMP RSV Test Immunoassay cartridge for rapid detection of respiratory syncytial virus (RSV), co-developed with 3M.
• RAMP COVID-19 Antigen Test Immunoassay cartridge for rapid detection of SARS-CoV-2 antigen, authorized for professional use and at-home testing under Health Canada approval (November 2022).
• RAMP Total β-hCG Test Quantitative immunoassay cartridge for total beta-human chorionic gonadotropin used in blood-based pregnancy testing for women's health and obstetrics settings.
• RAMP Arbovirus Tests Immunoassay cartridges for CDC-validated detection of mosquito-borne arboviruses including West Nile Virus, Dengue, and Zika, used by vector control and public health surveillance programs.
• RAMP Xpress Platform New diagnostic platform launched by Response Biomedical that extends the RAMP architecture beyond acute care into chronic disease and wellness management markets.
• RAMP 200 Barcode Scanner USB-connected, omni-directional, hands-free barcode scanner accessory for the RAMP 200 analyzer that scans operator and patient sample IDs.
• RAMP 200 Printer Compact, portable thermal printer accessory for the RAMP 200 analyzer with easy-to-open paper system for printing test results.
• RAMP Portal Customer-facing web portal for managing test results, data, and device connectivity for the RAMP diagnostic system.

Quantifiable outcome

• Lab-quality results in approximately 15 minutes
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Sugentech, Inc.coreStrategic or Co-development Partner · 24 March 2026Response Biomedical announced a strategic collaboration with Sugentech, Inc. (KOSDAQ: 253840) on March 24, 2026, to support the advancement and commercialization of a next-generation testing platform in high-growth global markets. This partnership extends Response's global distribution capabilities.
• IntertekcoreOthers · 1 July 2025Intertek provides ISO 13485:2016 and MDSAP certification services for Response Biomedical's Quality Management System, demonstrating regulatory compliance.
• Health CanadacoreOthers · 1 November 2024Health Canada granted approval for the RAMP COVID-19 antigen test, enabling Response Biomedical to distribute the test in Canada.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Siemens Healthineers: Operates established POC blood-gas/electrolyte/metabolite and immunoassay analyzers (RAPIDPoint, epoc) across acute-care settings and competes with RAMP for hospital POC budget.
• Roche Diagnostics: Roche's cobas and CARDIAC POC line compete head-on with RAMP in acute-care cardiac markers like Troponin T and NT-proBNP, backed by Roche's global central-lab and POC infrastructure.
• QuidelOrtho: Broader IVD/POC player (Triage MeterPro, Sofia, QuickVue) competing in quantitative cardiac and infectious-disease POC, with much larger commercial scale and a direct-plus-channel sales model.

Direct peers

• Sekisui Diagnostics: Develops and distributes IVD/POC test kits and platforms across cardiovascular, infectious disease, and other acute-care-adjacent indications, with both direct and channel sales.
• Werfen (Instrumentation Laboratory): Hemochron and related specialty POC coagulation/IVD systems directly overlap with RAMP's D-Dimer and cardiac marker portfolio in the same acute-care sales motion.
• Abbott (Point of Care / i-STAT): Abbott's i-STAT system is the closest direct comparable — a handheld quantitative POC immunoassay platform delivering lab-quality results from whole blood in minutes for cardiac, sepsis, and coagulation markers, sold into the same acute-care hospital channels.
• Nova Biomedical: Nova's StatStrip and Prime Plus blood-gas/chemistry POC analyzers target the same hospital acute-care workflow, with overlapping product positioning around quantitative, lab-quality point-of-care results.
• Helena Laboratories: Specialist in coagulation/hemostasis diagnostics, including POC and specialty lab reagents, with product overlap to RAMP's D-Dimer and coagulation-focused cardiac markers.

Emerging players

• HemoSonics: POC viscoelastic hemostasis diagnostics (Quantra) for cardiac surgery and critical care — operates in a closely adjacent acute-care diagnostics niche targeted by Response's coagulation menu.
• Boditech Med: Korean POCT specialist (ichroma II, AFIAS) selling quantitative POC immunoassays for cardiac, sepsis, and infectious markers — directly overlapping RAMP's application areas, primarily across APAC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/response-biomedical-corporation

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Response Biomedical